Scaling Innovation

What’s the best medicine for Life Sciences?

Join us May 5th for an exclusive virtual event where the boundaries, challenges, and opportunities of scaling innovation in the Life Sciences and MedTech industry will be discussed by our panel of leading experts from Medicon Valley.

This event is a collaboration with the Applied Innovation Exchange (AIE) Malmö and together with Novo Nordisk, Coloplast, and Ambu, we will provide you with insight into our latest research around ‘Scaling’ and an industry leader perspective on scaling innovation.

The event will take place Wednesday May 5th 17:00-18:00 CET and will be fully virtual.

Becoming proficient at scaling innovation is crucial, not only so that business may survive, but so it can thrive. However, in the healthcare industry, what does it mean to scale? With barriers like slow digital adoption and the necessary adherence to compliance and regulation, how might the healthcare industry foster its own culture of innovation despite regulation and sometimes lengthy time to market?

With personalized healthcare on the rise globally, how will life sciences scale speedy innovation with an increased patient-centric mindset that meets demand?

This recent pandemic has proven that the need for a more nimble approach is vital, so what is the future for the life sciences moving into a post-Covid world? What is the future we want and how can we get it?

Scaling Innovation – State of The Union

Introduction to our latest research – Scaling Innovation: What’s the Big Idea? Why most innovations fail to scale and what to do about it. We found that while companies are generally quite good at generating and incubating new ideas within innovation centers or open ecosystems, they are less successful at scaling the results, for reasons ranging from over-reliance on technology, to a lack of focus on what customers actually want.

However, companies can still get ahead in the game if they treat the achievement of scale as a specific and unique discipline, put in place the right innovation governance, and build a culture that encourages taking tough decisions on scaled innovations.

Panel Discussion with Industry Leaders

This pandemic has proven that the need for a more nimble approach is vital, so what is the future for the Life Sciences and MedTech in the COVID and post-COVID world?

With barriers like slow digital adoption and the necessary adherence to compliance and regulation, how might the industry foster its own innovation culture despite regulation and sometimes lengthy time to market?

And with personalized healthcare on the rise globally, how will Life Sciences & MedTech scale innovation with an increased patient-centric mindset that meets demand?

These are some of the topics our esteemed panelists will be discussing during this session. See the full list of panelists below.

Register

 

Thank You!

We are sorry, the form submission failed. Please try again.

 

Panelists:

Koray Karakaya
Vice President, New Business Innovation
Coloplast
Björg Áskelsdóttir
Executive Management Director, Global Innovation
Ambu
Meghan Young
Head of Research
Applied Innovation Exchange, Capgemini
Christian Jönsson
Corporate VP – Digital Incubator & Innovation
Novo Nordisk

Moderator 

Christina Lindved Turner
General Manager at Waters & Board Member
SSI Diagnostica A/S

Host

John Fodeh
Director of Life Sciences & MedTech
Capgemini